Literature DB >> 17181927

A proposal of new ocular items in Sjögren's syndrome classification criteria.

P Versura1, M Frigato, R Mulé, N Malavolta, E C Campos.   

Abstract

OBJECTIVE: To verify whether ocular surface tests other than those included in primary Sjögren's syndrome (SS-I) classification criteria (Schirmer I, Break up Time, vital dye staining) may contribute to SS I diagnosis.
METHODS: Two hundred and sixty-two patients (78 SS-1, 91 non-SS autoimmune diseases, 93 Sicca syndrome) filled a validated questionnaire on symptoms and were evaluated by Schirmer test without (Schirmer I) and with (Jones test) topical anaesthesia, Break Up Time (BUT), corneal aesthesiometry, tear clearance rate, vital dye (lissamine green) staining, impression conjunctival cytology, concentration of tear lysozyme and lactoferrin. Thresholds were selected from Receiver Operating Curves; sensitivity, specificity, likelihood ratio (LR+), predictive values were calculated for each test. A logistic regression model was constructed representing the best diagnostic index for SS.
RESULTS: Data showed a poor diagnostic performance of Schirmer test I (LR+ 1.38) and BUT (LR+ 1.05); results from lissamine green staining may be unreliable due to incorporation bias. Tear lactoferrin (LR+ 4.52), Jones test (LR+ 6.24), tear lysozyme (LR+ 8.0), symptom questionnaire (LR+ 8.62), tear clearance rate (LR+ 18.73) and corneal aesthesiometry (LR+ 20.96) exhibited high diagnostic performance also taken together in the regression model.
CONCLUSION: Because many of the tests we have screened in this study can be carried out by a trained ophthalmologist in any clinical setting, we recommend that ocular surface impairment is studied with the combination of tests proved to be helpful for the SS I diagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17181927

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  8 in total

1.  Ocular surface and intraocular inflammation are related in SS-I and rheumatoid arthritis patients.

Authors:  Mauro Cellini; Piera Versura; Pietro Leonetti; Marilena Frigato; Elena Manfredini; Nazzarena Malavolta; Emilio C Campos
Journal:  Rheumatol Int       Date:  2007-02-13       Impact factor: 2.631

Review 2.  Mouse Models of Primary Sjogren's Syndrome.

Authors:  Young-Seok Park; Adrienne E Gauna; Seunghee Cha
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

3.  Improved label-free LC-MS analysis by wavelet-based noise rejection.

Authors:  Salvatore Cappadona; Paolo Nanni; Marco Benevento; Fredrik Levander; Piera Versura; Aldo Roda; Sergio Cerutti; Linda Pattini
Journal:  J Biomed Biotechnol       Date:  2010-01-28

Review 4.  [Typical questions from the rheumatologist to the ophthalmologist and cooperating radiologist].

Authors:  B Nölle; M Both; M Heller; J B Roider
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

5.  A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren's Syndrome International Registry.

Authors:  John P Whitcher; Caroline H Shiboski; Stephen C Shiboski; Ana Maria Heidenreich; Kazuko Kitagawa; Shunhua Zhang; Steffen Hamann; Genevieve Larkin; Nancy A McNamara; John S Greenspan; Troy E Daniels
Journal:  Am J Ophthalmol       Date:  2009-12-29       Impact factor: 5.258

Review 6.  Practical issues concerning tear protein assays in dry eye.

Authors:  Sharon D'Souza; Louis Tong
Journal:  Eye Vis (Lond)       Date:  2014-11-13

7.  Ocular Clinical Signs and Diagnostic Tests Most Compatible With Keratoconjunctivitis Sicca: A Latent Class Approach.

Authors:  John A Gonzales; Stephen C Shiboski; Vatinee Y Bunya; Esen K Akpek; Jennifer Rose-Nussbaumer; Gerami D Seitzman; Lindsey A Criswell; Caroline H Shiboski; Thomas M Lietman
Journal:  Cornea       Date:  2020-08       Impact factor: 3.152

8.  Unstimulated whole saliva flow for diagnosis of primary Sjögren's syndrome: time to revisit the threshold?

Authors:  Valentin Lacombe; Carole Lacout; Pierre Lozac'h; Alaa Ghali; Aline Gury; Christian Lavigne; Geoffrey Urbanski
Journal:  Arthritis Res Ther       Date:  2020-02-24       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.